TD Cowen Maintains Buy on Revolution Medicines, Raises Price Target to $270
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Tyler Van Buren maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $250 to $270.
TD Cowen analyst Tyler Van Buren maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $250 to $270.